Virologica Sinica

, Volume 29, Issue 1, pp 10–16 | Cite as

New therapeutic vaccination strategies for the treatment of chronic hepatitis B

  • Jia Liu
  • Anna Kosinska
  • Mengji Lu
  • Michael RoggendorfEmail author


Chronic hepatitis B virus (CHB) is currently treated with either interferon-based or nucleot(s)ide-based antiviral therapies. However, treatment with pegylated interferon alpha results in a durable antiviral response in only about 30% patients and is associated with side effects. Most patients receiving nucleot(s)ide analogue treatment do not establish long-term, durable control of infection and have rebounding viremia after cessation of therapy. Thus, novel therapy strategies are necessary to achieve the induction of potent and durable antiviral immune responses of the patients which can maintain long-term control of viral replication. Therapeutic vaccination of HBV carriers is a promising strategy for the control of hepatitis B. Here the authors review new therapeutic vaccination strategies to treat chronic hepatitis B which may be introduced for patient treatment in the future.


hepatitis B virus woodchuck hepatitis virus therapeutic vaccination immunomodulation programmed death-1 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barber D L, Wherry E J, Masopust D, Zhu B, Allison J P, Sharpe A H, Freeman G J, and Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439: 682–687.PubMedCrossRefGoogle Scholar
  2. Blum H E, Gerok W, and Vyas G N. 1989. The molecular biology of hepatitis B virus. Trends Genet: TIG, 5: 154–158.PubMedCrossRefGoogle Scholar
  3. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, and Ferrari C. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest, 102: 968–975.PubMedCentralPubMedCrossRefGoogle Scholar
  4. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, and Ferrari C. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol, 81: 4215–4225.PubMedCentralPubMedCrossRefGoogle Scholar
  5. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, and Ferrari C. 2003. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol, 39: 595–605.PubMedCrossRefGoogle Scholar
  6. Chisari F V, Isogawa M, and Wieland S F. 2010. Pathogenesis of hepatitis B virus infection. Pathol Biol, 58: 258–266.PubMedCentralPubMedCrossRefGoogle Scholar
  7. Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, and Michel M L. 1999. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis, 180: 15–26.PubMedCrossRefGoogle Scholar
  8. Dahmen A, Herzog-Hauff S, Bocher W O, Galle P R, and Lohr H F. 2002. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol, 66: 452–460.PubMedCrossRefGoogle Scholar
  9. Dandri M, and Locarnini S. 2012. New insight in the pathobiology of hepatitis B virus infection. Gut, 61 Suppl 1: i6–17.CrossRefGoogle Scholar
  10. Day C L, Kaufmann D E, Kiepiela P, Brown J A, Moodley E S, Reddy S, Mackey E W, Miller J D, Leslie A J, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry E J, Coovadia H M, Goulder P J, Klenerman P, Ahmed R, Freeman G J, and Walker B D. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 443: 350–354.PubMedCrossRefGoogle Scholar
  11. Dikici B, Bosnak M, Ucmak H, Dagli A, Ece A, and Haspolat K. 2003. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroen Hepatol, 18: 218–222.CrossRefGoogle Scholar
  12. Fiedler M, Kosinska A, Schumann A, Brovko O, Walker A, Lu M, Johrden L, Mayer A, Wildner O, and Roggendorf M. 2013. Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus. J Virol, 87: 7708–7716.PubMedCentralPubMedCrossRefGoogle Scholar
  13. Finnefrock A C, Tang A, Li F, Freed D C, Feng M, Cox K S, Sykes K J, Guare J P, Miller M D, Olsen D B, Hazuda D J, Shiver J W, Casimiro D R, and Fu T M. 2009. PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol, 182: 980–987.PubMedGoogle Scholar
  14. Freeman G J, Wherry E J, Ahmed R, and Sharpe A H. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med, 203: 2223–2227.PubMedCentralPubMedCrossRefGoogle Scholar
  15. Ganem D, and Prince A M. 2004. Hepatitis B virus infection—natural history and clinical consequences. New Engl J Med, 350: 1118–1129.PubMedCrossRefGoogle Scholar
  16. Ha S J, Mueller S N, Wherry E J, Barber D L, Aubert R D, Sharpe A H, Freeman G J, and Ahmed R. 2008. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med, 205: 543–555.PubMedCentralPubMedCrossRefGoogle Scholar
  17. Hervas-Stubbs S, Lasarte J J, Sarobe P, Vivas I, Condreay L, Cullen J M, Prieto J, and Borras-Cuesta F. 2001. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol, 35: 105–111.PubMedCrossRefGoogle Scholar
  18. Horiike N, Fazle Akbar S M, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, and Onji M. 2005. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol: the official publication of the Pan American Society for Clinical Virology, 32: 156–161.CrossRefGoogle Scholar
  19. Jung M C, Spengler U, Schraut W, Hoffmann R, Zachoval R, Eisenburg J, Eichenlaub D, Riethmuller G, Paumgartner G, Ziegler-Heitbrock H W, and et al. 1991. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol, 13: 310–317.PubMedCrossRefGoogle Scholar
  20. Jung M C, Gruner N, Zachoval R, Schraut W, Gerlach T, Diepolder H, Schirren C A, Page M, Bailey J, Birtles E, Whitehead E, Trojan J, Zeuzem S, and Pape G R. 2002. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine, 20: 3598–3612.PubMedCrossRefGoogle Scholar
  21. Kosinska A D, Johrden L, Zhang E, Fiedler M, Mayer A, Wildner O, Lu M, and Roggendorf M. 2012. DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol, 86: 9297–9310.PubMedCentralPubMedCrossRefGoogle Scholar
  22. Kosinska A D, Zhang E, Johrden L, Liu J, Seiz P L, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, and Roggendorf M. 2013. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog, 9: e1003391.PubMedCentralPubMedCrossRefGoogle Scholar
  23. Li F J, Zhang Y, Jin G X, Yao L, and Wu D Q. 2013. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett, 150: 116–122.PubMedCrossRefGoogle Scholar
  24. Liang T J. 2009. Hepatitis B: the virus and disease. Hepatology, 49: S13–21.PubMedCentralPubMedCrossRefGoogle Scholar
  25. Locarnini S, and Mason W S. 2006. Cellular and virological mechanisms of HBV drug resistance. J Hepatol, 44: 422–431.PubMedCrossRefGoogle Scholar
  26. Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, Chi H, Dirsch O, Kemper T, He L, Glebe D, Gerlich W H, Wen Y, and Roggendorf M. 2008. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol, 82: 2598–2603.PubMedCentralPubMedCrossRefGoogle Scholar
  27. Maier H, Isogawa M, Freeman G J, and Chisari F V. 2007. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol, 178: 2714–2720.PubMedGoogle Scholar
  28. Maini M K, Boni C, Lee C K, Larrubia J R, Reignat S, Ogg G S, King A S, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov N V, Ferrari C, and Bertoletti A. 2000. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med, 191: 1269–1280.PubMedCentralPubMedCrossRefGoogle Scholar
  29. Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, and Michel M L. 2006. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine, 24: 4482–4489.PubMedCrossRefGoogle Scholar
  30. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, and Michel M L. 2004. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology, 40: 874–882.PubMedGoogle Scholar
  31. Menne S, Roneker C A, Tennant B C, Korba B E, Gerin J L, and Cote P J. 2002. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology, 45: 237–250.PubMedCrossRefGoogle Scholar
  32. Menne S, Roneker C A, Korba B E, Gerin J L, Tennant B C, and Cote P J. 2002. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol, 76: 5305–5314.PubMedCentralPubMedCrossRefGoogle Scholar
  33. Paoletti E. 1996. Applications of pox virus vectors to vaccination: an update. P Natl Acad Sci USA, 93: 11349–11353.CrossRefGoogle Scholar
  34. Penna A, Chisari F V, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, and Ferrari C. 1991. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med, 174: 1565–1570.PubMedCrossRefGoogle Scholar
  35. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, and Ferrari C. 2007. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology, 45: 588–601.PubMedCrossRefGoogle Scholar
  36. Perkus M E, Piccini A, Lipinskas B R, and Paoletti E. 1985. Recombinant vaccinia virus: immunization against multiple pathogens. Science, 229: 981–984.PubMedCrossRefGoogle Scholar
  37. Petrovas C, Casazza J P, Brenchley J M, Price D A, Gostick E, Adams W C, Precopio M L, Schacker T, Roederer M, Douek D C, and Koup R A. 2006. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med, 203: 2281–2292.PubMedCentralPubMedCrossRefGoogle Scholar
  38. Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky J M, Zeuzem S, Schalm S W, von Wagner M, Germanidis G, Lurie Y, Esteban J I, Haagmans B L, Hezode C, Lagging M, Negro F, Homburger Y, Neumann A U, Ferrari C, and Missale G. 2007. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology, 133: 1132–1143.PubMedCrossRefGoogle Scholar
  39. Pol S, Driss F, Michel M L, Nalpas B, Berthelot P, and Brechot C. 1994. Specific vaccine therapy in chronic hepatitis B infection. Lancet, 344: 342.PubMedCrossRefGoogle Scholar
  40. Pol S, Nalpas B, Driss F, Michel M L, Tiollais P, Denis J, and Brecho C. 2001. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol, 34: 917–921.PubMedCrossRefGoogle Scholar
  41. Rehermann B, and Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol, 5: 215–229.PubMedCrossRefGoogle Scholar
  42. Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A, Ishiko H, Furutani M, Yamasaki T, Korenaga K, Yamashita S, Konishi T, and Okita K. 2003. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol, 71: 376–384.PubMedCrossRefGoogle Scholar
  43. Robinson H L. 2002. New hope for an AIDS vaccine. Nature reviews. Immunology, 2: 239–250.PubMedCrossRefGoogle Scholar
  44. Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A, Rowe M, Alper R, Klein A, Hemed N, Segol O, Thalenfeld B, Engelhardt D, Rabbani E, and Ilan Y. 2003. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol, 98: 2505–2515.PubMedCrossRefGoogle Scholar
  45. Sallberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend K, Anderson C G, O’Dea J, Alfonso J, Eason R, Murthy K K, Jolly D J, Chang S M, Mento S J, Milich D, and Lee W T. 1998. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther, 9: 1719–1729.PubMedCrossRefGoogle Scholar
  46. Schurich A, Khanna P, Lopes A R, Han K J, Peppa D, Micco L, Nebbia G, Kennedy P T, Geretti A M, Dusheiko G, and Maini M K. 2011. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology, 53: 1494–1503.PubMedCrossRefGoogle Scholar
  47. Tatsis N, and Ertl H C. 2004. Adenoviruses as vaccine vectors. Mol Ther, 10: 616–629.PubMedCrossRefGoogle Scholar
  48. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann K A, Purcell R H, and Chisari F V. 2003. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 77: 68–76.PubMedCentralPubMedCrossRefGoogle Scholar
  49. Trautmann L, Janbazian L, Chomont N, Said E A, Gimmig S, Bessette B, Boulassel M R, Delwart E, Sepulveda H, Balderas R S, Routy J P, Haddad E K, and Sekaly R P. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med, 12: 1198–1202.PubMedCrossRefGoogle Scholar
  50. Vandepapeliere P, Lau G K, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican M I, Win K M, Trepo C, Cooksley G, Wettendorff M, and Ferrari C. 2007. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine, 25: 8585–8597.PubMedCrossRefGoogle Scholar
  51. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford T H, Chennareddi L, Silvestri G, Freeman G J, Ahmed R, and Amara R R. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature, 458: 206–210.PubMedCentralPubMedCrossRefGoogle Scholar
  52. Wang X Y, Zhang X X, Yao X, Jiang J H, Xie Y H, Yuan Z H, and Wen Y M. 2010. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine, 28: 8169–8174.PubMedCrossRefGoogle Scholar
  53. Webster G J, Reignat S, Brown D, Ogg G S, Jones L, Seneviratne S L, Williams R, Dusheiko G, and Bertoletti A. 2004. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol, 78: 5707–5719.PubMedCentralPubMedCrossRefGoogle Scholar
  54. Wen Y M, Wu X H, Hu D C, Zhang Q P, and Guo S Q. 1995. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet, 345: 1575–1576.PubMedCrossRefGoogle Scholar
  55. Wu C, Shi H, Wang Y, Lu M, Xu Y, and Chen X. 2012. A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy. Virol Sin, 27: 369–372.PubMedCrossRefGoogle Scholar
  56. Wu W, Shi Y, Li S, Zhang Y, Liu Y, Wu Y, and Chen Z. 2012. Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. Eur J Immunol, 42: 1180–1191.PubMedCrossRefGoogle Scholar
  57. Xu D Z, Zhao K, Guo L M, Li L J, Xie Q, Ren H, Zhang J M, Xu M, Wang H F, Huang W X, Bai X F, Niu J Q, Liu P, Chen X Y, Shen X L, Yuan Z H, Wang X Y, and Wen Y M. 2008. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PloS One, 3: e2565.PubMedCentralPubMedCrossRefGoogle Scholar
  58. Xu D Z, Wang X Y, Shen X L, Gong G Z, Ren H, Guo L M, Sun A M, Xu M, Li L J, Guo X H, Zhen Z, Wang H F, Gong H Y, Xu C, Jiang N, Pan C, Gong Z J, Zhang J M, Shang J, Xu J, Xie Q, Wu T F, Huang W X, Li Y G, Yuan Z H, Wang B, Zhao K, and Wen Y M. 2013. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol, 59: 450–456.PubMedCrossRefGoogle Scholar
  59. Yalcin K, Acar M, and Degertekin H. 2003. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection, 31: 221–225.PubMedGoogle Scholar
  60. Yang P L, Althage A, Chung J, Maier H, Wieland S, Isogawa M, and Chisari F V. 2010. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A, 107: 798–802.PubMedCentralPubMedCrossRefGoogle Scholar
  61. Yao X, Zheng B, Zhou J, Xu D Z, Zhao K, Sun S H, Yuan Z H, and Wen Y M. 2007. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine, 25: 1771–1779.PubMedCrossRefGoogle Scholar
  62. Zoulim F, and Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 137: 1593–1608 e1591–1592.PubMedCrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Jia Liu
    • 1
  • Anna Kosinska
    • 1
  • Mengji Lu
    • 1
  • Michael Roggendorf
    • 1
    Email author
  1. 1.Institute for VirologyUniversity Hospital of Essen, University of Duisburg-EssenEssenGermany

Personalised recommendations